Holen Sie sich die Stockscreener-App
0.7047
1.50%
0.0104
Schlusskurs vom Vortag:
$0.6943
Offen:
$0.7
24-Stunden-Volumen:
8,997
Relative Volume:
0.22
Marktkapitalisierung:
$4.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.68M
KGV:
-0.0589
EPS:
-11.96
Netto-Cashflow:
$-36.70M
1W Leistung:
+5.97%
1M Leistung:
-6.05%
6M Leistung:
-39.77%
1J Leistung:
-77.34%
1-Tages-Spanne:
$0.68
$0.72
1-Wochen-Bereich:
$0.59
$0.74
52-Wochen-Spanne:
$0.5525
$4.47
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Firmenname
Hepion Pharmaceuticals Inc
Sektor
Branche
Telefon
732-902-4000
Adresse
399 THORNALL STREET, EDISON
Vergleichen Sie HEPA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| HEPA | 0.69 | 4.06M | 0 | -44.68M | -36.70M | -11.96 |
| VRTX | 450.19 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.38 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.25 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.35 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-07-20 | Fortgesetzt | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc Aktie (HEPA) Neueste Nachrichten
Hepion Pharmaceuticals Inc (CTVRP) Quarterly 10-Q Report - Quartzy
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger - The Manila Times
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce - GlobeNewswire
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67% - MSN
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Will Hepion's AMBITION Be Fulfilled? - RTTNews
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Hypha Labs, Inc. Releases Investor Presentation - AccessWire
Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register
FluoRok raises US$ 9.8million for safety and sustainability of fluorochemical production - Indian Chemical News
FLO stock rated an Underperform by Exane BNP Paribas - Knox Daily
Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat
Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat
FluoRok Raises £7.7M in Funding - FinSMEs
Oxford's FluoRok secures €9.2M from BGF and others - Silicon Canals
HilleVax, Inc. (NASDAQ:HLVX) Given Consensus Rating of “Hold” by Analysts - Defense World
PHINIA Inc. (NYSE:PHIN) Shares Acquired by Long Road Investment Counsel LLC - Defense World
King Luther Capital Management Corp Boosts Position in Helios Technologies, Inc. (NASDAQ:HLIO) - Defense World
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update - Defense World
Hepion Pharmaceuticals faces Nasdaq delisting over share price - Investing.com
Pharma Two B and Hepion Pharmaceuticals file for merger - Investing.com
Pharma Two B and Hepion Pharmaceuticals file for merger By Investing.com - Investing.com UK
Hepion, Pharma Two B file registration statement for proposed merger - TipRanks
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - ForexTV.com
Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 4.7% Higher - Defense World
TNF Pharmaceuticals (NASDAQ:TNFA) Stock Quotes, Forecast and News Summary - Benzinga
HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024 - MSN
HEPION PHARMACEUTICALS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
GSK, Novartis lead July deals as biopharma sector sees more than $20B for the month - BioWorld Online
Hepion Pharmaceuticals announces executive leadership changes - Investing.com India
Hepion Pharmaceuticals announces executive leadership changes By Investing.com - Investing.com UK
Following restructuring, Hepion to merge with Israeli pharma firm - NJBIZ
Cingulate (NASDAQ:CING) Stock Quotes, Forecast and News Summary - Benzinga
HEPA hits 52-week low, trading at 0.7324 USD - Investing.com
HEPA hits 52-week low, trading at 0.7324 USD By Investing.com - Investing.com Canada
Oligonucleotide Therapy Market Targeting the Future of Medicine: Oligonucleotide Therapies Offer Precision ... - WhaTech
Financial Health Check: Examining Hepion Pharmaceuticals Inc (HEPA)’s Key Ratios - The Dwinnex
Aurora Innovation Inc [AUR] Is Currently -0.71 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Oligonucleotide Therapy Market to Reach USD 19.92 Billion by 2031 | InsightAce Analytic - openPR
The Globe and Mail - The Globe and Mail
Oligonucleotide Therapy Market Transforming Healthcare: - openPR
Hepion Pharmaceuticals Inc’s Banking’s 100-Day Moving Average at 1.6118: Will the Stock Break Through? - The InvestChronicle
The Hepion Pharmaceuticals Inc (HEPA) Stock Is Headed for a Correction - US Post News
IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings - Markets Insider
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer - Benzinga
Hepion Pharmaceuticals’ Strategic Merger and Corporate Restructuring - TipRanks
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement - StockTitan
HEPAHepion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News Summary - Benzinga
Biogen Inc. to Post Q2 2024 Earnings of $4.12 Per Share, Leerink Partnrs Forecasts (NASDAQ:BIIB) - American Banking and Market News
Finanzdaten der Hepion Pharmaceuticals Inc-Aktie (HEPA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):